Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 26Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 8Adenocarcinoma 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Salivary Gland Neoplasms 3Recurrence 3HER2-positive Breast Cancer 3Advanced Solid Tumor 3Advanced Breast Cancer 3Sarcoma 2Prostatic Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Cancer With Brain Metastasis 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × trastuzumab deruxtecan × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡